Pharmaceutical Technology, Nov 1, 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Nov 1, 2007
Articles
Going Mobile
By Richard W. Padula
Seven Reasons Why Pharmaceutical Makers Are Adopting Mobile Technology
Defragmenting GRC: Confidence and Cost-Efficiency in a Time of Chaos
By Brett Curran
The scope and complexity of GRC requirements are expanding so rapidly that businesses are struggling to fulfill them despite an increased willingness on industry's part to apply additional GRC resources.
Tech Talk: A Q&A with Oracle's Arvindh Balakrishnan
By Michelle Hoffman

The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward virtualization, among other things.

Do you have something to ask Arvindh Balakrishnan? Click here to submit your questions.

The Challenge in Bioprocess Development: From Data to Knowledge
By Gary Montague , Elaine Martin
The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward visualization, among other things.
Determining LIMS Functionality, Cost, and ROI: System Architecture Strengths and Limitations
By Ron Kasner
Before any information technology solution can be installed, a company must decide whether applications are going to reside on individual computers at each employee's workstation, on servers within or outside of an organization, or on a vendor's website.
The New Biopharmaceutical Blueprint: Service-Oriented Architecture in Manufacturing
By Pieter Deurinck , Jay DiMare , Michael T. Ricci , Kathleen Martin
More than ever, drug makers need to be fleet and flexible—and they need their software to be the same.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here